Here are the latest stories being discussed in biopharma today:

1. “An Insight into Beam CEO John Evans’s approach to Genetic Editing”
Beam Therapeutics CEO John Evans recently shared his views about the science and business aspects of genetic editing, which sheds light on how the company plans to approach this sector. Beam started 202